Cosciens closes second tranche of convertible debenture offering
Cosciens Biopharma says it has closed the second tranche of a non-brokered private placement of 15% unsecured convertible debentures, further to its Sept. 10, 2026 press release.
Story updates
10:03:20 PM UTC
SquawkNews
COSCIENS closed a second tranche of its 15% unsecured convertible debenture offering, adding $4.375M and bringing the total to $10.706M toward a planned $20M. Conversion terms need shareholder approval to be sought within six months.Material DetailsContext by AI AnalystThis continues a recent fundi…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.